Table 1.
Population characteristics.
| OPGs | n = 26 |
|---|---|
| Gender | |
| Male | 13/26 (50%) |
| Female | 13/26 (50%) |
| Age at diagnosis (months) | |
| Median (months) | 40.7 |
| Range (months) | 3.0–201.7 |
| Dodge classification | |
| Stage 1 | 1/26 (4%) |
| Stage 2 | 6/26 (23%) |
| Stage 3 | 19/26 (73%) |
| Hypothalamic involvement | 18/26 (70%) |
| Type | |
| NF1 | 5/26 (19%) |
| Sporadic | 21/26 (81%) |
| Surgery | |
| Biopsy | 13/26 (50%) |
| Microsurgical debulking | 13/26 (50%) |
| Ventriculoperitoneal shunt (VPS) | 9/26 (35%) |
| Upfront Treatment | 26/26 (100%) |
| Chemotherapy | 23/26 (88%) |
| Target therapy | 3/26 (12%) |
| Second-third line treatment | 10/26 (42%) |
| Chemotherapy 2ndline | 2/26 (8%) |
| Target therapy | 8/26 (31%) |